약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 2.

Table. 2. Spending trends of high-priced medicines by drug characteristics: supplier type, RSA, ATC category (unit: 1,000,000 KRW)
Category 2010 2012 2014 2016 2018 2020 2021 (%) CAGR
Total spending 388,347 441,905 540,692 661,778 1,031,876 1,398,519 1,692,784 (100.0%) 14.3%
Cost per patient (million KRW/patient)
Low (10~50) 244,250 295,605 314,494 495,781 786,142 1,053,809 1,338,681 (79.1%) 16.7%
Middle (50~100) 100,975 74,963 83,733 36,268 74,312 98,433 101,251 (6.0%) 0.0%
High (100~300) 24,660 36,370 64,549 77,709 64,179 86,905 176,676 (10.4%) 19.6%
Extra high (300+) 18,462 34,966 77,916 52,020 107,243 159,372 76,176 (4.5%) 13.8%
Supplier type
International 289,683 397,637 463,042 557,588 812,389 1,065,326 1,241,635 (73.3%) 14.1%
Domestic 98,664 44,268 77,649 104,190 219,487 333,193 451,149 (26.7%) 14.8%
RSA listed
RSA 0 0 31,977 133,142 484,547 730,361 959,032 (56.7%) 62.6%
RSA finished 0 0 0 0 0 72,168 75,663 (4.5%)
non-RSA 388,347 441,905 508,714 528,636 547,330 595,991 658,089 (38.9%) 4.9%
ATC category
A10A 25
A16A 23,814 46,276 60,680 81,387 92,295 110,203 122,100 (7.2%) 16.0%
B01A 370 602 1,371 5,574 12,367 14,062 (0.8%) 49.8%
B02B 121,423 127,213 156,958 170,065 188,856 207,367 207,974 (12.3%) 5.0%
B05D 16,087 8,753
C02K 8,245 11,425 14,222 2,871 12,453 19,082 21,634 (1.3%) 9.2%
D11A 48,286 (2.9%)
H01C 7,542 9,068 10,342 4,875 11,808 13,140 7,304 (0.4%) -0.3%
J02A 10,930
J04A 3,260 7,028 7,817 11,944 (0.7%) 29.7%
J05A 109,743 53,915 44,941 49,199 (2.9%) -14.8%
J06B 47,001
L01A 822 1,375 2,256 2,664 2,894
L01B 7,561 10,130 15,543 16,248 19,386 5,897 72 (0.0%) -34.5%
L01E 95,831 115,372 96,044 161,597 313,930 453,427 516,100 (30.5%) 16.5%
L01F 42,372 85,371 111,455 28,819 192,548 297,175 440,530 (26.0%) 23.7%
L01X 11,865 18,676 22,814 1,181 28,452 57,775 70,485 (4.2%) 17.6%
L02B 16,308 21,511 22,331 24,031 (1.4%) 8.1%
L03A 6,606 8,207 8,587 3,825 7,365 5,698 6,736 (0.4%) 0.2%
L04A 221 30,639 57,972 74,092 93,172 109,752 (6.5%) 99.3%
M09A 42,452 38,193 (2.3%)
N03A 503 1,186
N07X 1,450 1,848 (0.1%)
S01G 123 218 (0.0%)
V09I 706 (0.0%)
V10X 1,614 (0.1%)

Note. ATC 3-level names are: A10A-insulins and analogues; A16A-other alimentary tract and metabolism products; B01A-antithrombotic agents; B02B-vitamin k and other hemostatics; B05D-peritoneal dialytics; C02K-other antihypertensives; D11A-other dermatological preparations; H01C-hypothalamic hormones; J02A-antimycotics for systemic use; J04A-drugs for treatment of tuberculosis; J05A-direct acting antivirals; J06B-immunoglobulins; L01A-alkylating agents; L01B-antimetabolites; L01E-protein kinase inhibitors; L01F-monoclonal antibodies and antibody drug conjugates; L01X-other antineoplastic agents; L02B-hormone antagonists and related agents; L03A-immunostimulants; L04A-immunosuppressants; M09A-other drugs for disorders of the musculo-skeletal system; N03A-antiepileptics; N07X-other nervous system drugs; S01G-decongestants and antiallergics; V09I-tumour detection; V10X-other therapeutic radiopharmaceuticals;

Yakhak Hoeji 2023;67:388-97 https://doi.org/10.17480/psk.2023.67.6.388
© 2023 Yakhak Hoeji